Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation

Leukemia Research

Volumn 30, Issue 7, 2006, Pages 785-794

  Orsini, Enrica ^a   Calabrese, Elisabetta ^a   Maggio, Roberta ^a   Pasquale, Alessia ^a   Nanni, Mauro ^a   Trasarti, Stefania ^a   Tafuri, Agostino ^a   Guarini, Anna ^a   Foa, Robert ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bcr abl; Chronic myelogenous leukemia; Costimulatory molecules; Dendritic cells; T cells

Indexed keywords

B7 ANTIGEN; BCR ABL PROTEIN; CD40 ANTIGEN; CYTOKINE;

ANTIGEN RECOGNITION; ARTICLE; BONE MARROW CELL; CANCER PATIENT; CELL ISOLATION; CELL SURFACE; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VIVO STUDY; LEUKEMIA CELL; MOLECULAR RECOGNITION; MORPHOLOGICAL TRAIT; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD1; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, CHRONIC; LIPOPOLYSACCHARIDES; PHENOTYPE; SENSITIVITY AND SPECIFICITY; TRANSLOCATION, GENETIC;

EID: 33744542338     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.11.028     Document Type: Article

References (53)

1. Fialkow P.J., Jacobson R.J., and Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 63 (1977) 125-130
2. Sawyers C.L. Chronic myeloid leukemia. N Engl J Med 340 (1999) 1330-1340
3. Deininger M.W., Goldman J.M., and Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 96 (2000) 3343-3356
4. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature 243 (1973) 290-293
5. Kloetzer W., Kurzrock R., Smith L., et al. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 140 (1985) 230-238
6. Salgia R., Li J.L., Ewaniuk D.S., et al. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest 100 (1997) 46-57
7. Yotnda P., Firat H., Garcia-Pons F., et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 101 (1998) 2290-2296
8. Bosch G.J., Joosten A.M., Kessler J.H., Melief C.J., and Leeksma O.C. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88 (1996) 3522-3527
9. Bocchia M., Korontsvit T., Xu Q., et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87 (1996) 3587-3592
10. Pinilla-Ibarz J., Cathcart K., Korontsvit T., et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95 (2000) 1781-1787
11. Cathcart K., Pinilla-Ibarz J., Korontsvit T., et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103 (2004) 1037-1042
12. Takahashi T., Tanaka Y., Nieda M., et al. Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res 27 (2003) 795-802
13. Ossenkoppele G.J., Stam A.G., Westers T.M., et al. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 17 (2003) 1424-1426
14. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90 (1997) 3245-3287
15. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
16. Liu Y.J. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106 (2001) 259-262
17. Timmerman J.M., Czerwinski D.K., Davis T.A., et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99 (2002) 1517-1526
18. Choudhury A., Gajewski J.L., Liang J.C., et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 89 (1997) 1133-1142
19. Eibl B., Ebner S., Duba C., et al. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer 20 (1997) 215-223
20. Muller L., Provenzani C., Faul C., and Pawelec G. Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells. Br J Haematol 112 (2001) 740-748
21. Nieda M., Nicol A., Kikuchi A., et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 91 (1998) 977-983
22. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86 (1995) 2041-2050
23. Gilleece M.H., and Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma 44 (2003) 23-28
24. Enk A.H., Jonuleit H., Saloga J., and Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73 (1997) 309-316
25. Almand B., Resser J.R., Lindman B., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6 (2000) 1755-1766
26. Orsini E., Guarini A., Chiaretti S., Mauro F.R., and Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res 63 (2003) 4497-4506
27. Mohty M., Jarrossay D., Lafage-Pochitaloff M., et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 98 (2001) 3750-3756
28. Dong R., Cwynarski K., Entwistle A., et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood 101 (2003) 3560-3567
29. Eisendle K., Lang A., Eibl B., et al. Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia. Br J Haematol 120 (2003) 63-73
30. Mohty M., Isnardon D., Vey N., et al. Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+/CD38-primitive haematopoietic progenitors. Br J Haematol 119 (2002) 115-118
31. Arnoldus E.P., Wiegant J., Noordermeer I.A., et al. Detection of the Philadelphia chromosome in interphase nuclei. Cytogenet Cell Genet 54 (1990) 108-111
32. Jefford M., Schnurr M., Toy T., et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood 102 (2003) 1753-1763
33. Ardavin C., Martinez del Hoyo G., Martin P., et al. Origin and differentiation of dendritic cells. Trends Immunol 22 (2001) 691-700
34. MacDonald K.P., Munster D.J., Clark G.J., Dzionek A., Schmitz J., and Hart D.N. Characterization of human blood dendritic cell subsets. Blood 100 (2002) 4512-4520
35. Martin P., del Hoyo G.M., Anjuere F., et al. Concept of lymphoid versus myeloid dendritic cell lineages revisited: both CD8 alpha (-) and CD8 alpha (+) dendritic cells are generated from CD4 (low) lymphoid-committed precursors. Blood 96 (2000) 2511-2519
36. Rissoan M.C., Soumelis V., Kadowaki N., et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283 (1999) 1183-1186
37. Dzionek A., Fuchs A., Schmidt P., et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 165 (2000) 6037-6046
38. Boussiotis V.A., Freeman G.J., Gray G., Gribben J., and Nadler L.M. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 178 (1993) 1753-1763
39. Freeman G.J., Boussiotis V.A., Anumanthan A., et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2 (1995) 523-532
40. Kuchroo V.K., Das M.P., Brown J.A., et al. B7-1 and B7-2 costimulatory molecules activate differentially the Thl/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80 (1995) 707-718
41. Foy T.M., Aruffo A., Bajorath J., Buhlmann J.E., and Noelle R.J. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 14 (1996) 591-617
42. Kikuchi K., Yanagawa Y., Iwabuchi K., and Onoe K. Differential role of mitogen-activated protein kinases in CD40-mediated IL-12 production by immature and mature dendritic cells. Immunol Lett 89 (2003) 149-154
43. Pawelec G., Rehbein A., Schlotz E., and da Silva P. Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. Cancer Immunol Immunother 42 (1996) 193-199
44. Schulz U., Munker R., Ertl B., Holler E., and Kolb H.J. Different types of human leukemias express the message for TNF-alpha and interleukin-10. Eur J Med Res 6 (2001) 359-363
45. Brown R.D., Pope B., Murray A., et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 98 (2001) 2992-2998
46. Heisterkamp N., Stephenson J.R., Groffen J., et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306 (1983) 239-242
47. Ben-Neriah Y., Daley G.Q., Mes-Masson A.M., Witte O.N., and Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233 (1986) 212-214
48. Zorn E., Orsini E., Wu C.J., et al. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. Transplantation 71 (2001) 1131-1137
49. Bocchia M., Gentili S., Abruzzese E., et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365 (2005) 657-662
50. Bertazzoli C., Marchesi E., Passoni L., et al. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients. Clin Cancer Res 6 (2000) 1931-1935
51. Guarini A., Breccia M., Montefusco E., et al. Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission. Br J Haematol 113 (2001) 136-142
52. Reuben J.M., Lee B.N., Johnson H., Fritsche H., Kantarjian H.M., and Talpaz M. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha. Clin Cancer Res 6 (2000) 1671-1677
53. Molldrem J.J., Lee P.P., Wang C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6 (2000) 1018-1023